| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $27,736,914 | 43 | 100 |
| Dahl Andrew M. | SVP, Corporate Controller | 0 | $0 | 2 | $98,387 | $-98,387 |
| STONE HEISZ LESLIE | director | 0 | $0 | 1 | $218,120 | $-218,120 |
| Bruls Annette | CVP, EMEACLA | 0 | $0 | 1 | $237,907 | $-237,907 |
| Lippis Daniel J. | CVP, JAPAC | 0 | $0 | 13 | $924,639 | $-924,639 |
| Markowitz Wayne | CVP, JAPAC | 0 | $0 | 5 | $1.04M | $-1.04M |
| Chopra Daveen | CVP, TMTT & Surgical | 0 | $0 | 3 | $3.19M | $-3.19M |
| Ullem Scott B. | CVP, Chief Financial Officer | 0 | $0 | 4 | $3.87M | $-3.87M |
| Zovighian Bernard J | CEO | 0 | $0 | 6 | $7M | $-7M |
| BOBO DONALD E JR | CVP,Strategy/Corp Development | 0 | $0 | 8 | $11.15M | $-11.15M |
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and …
Over the last 12 months, insiders at Edwards Lifesciences Corporation have bought $0 and sold $27.74M worth of Edwards Lifesciences Corporation stock.
On average, over the past 5 years, insiders at Edwards Lifesciences Corporation have bought $109,049 and sold $42.64M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 580 shares for transaction amount of $49,753 was made by Zovighian Bernard J (CEO) on 2024‑05‑06.
| 2026-10-08 | Sale | Lippis Daniel J. | CVP, TAVR | 619 0.0001% | $85.65 | $53,017 | +5.34% | |
| 2026-09-11 | Sale | Lippis Daniel J. | CVP, TAVR | 619 0.0001% | $87.51 | $54,169 | +3.39% | |
| 2026-08-31 | Sale | Dahl Andrew M. | SVP, Corporate Controller | 544 <0.0001% | $91.06 | $49,534 | -3.88% | |
| 2026-08-28 | Sale | Bruls Annette | CVP, EMEACLA | 2,644 0.0005% | $89.98 | $237,907 | -2.83% | |
| 2026-08-26 | Sale | Chopra Daveen | CVP, TMTT, Surgical & IHFM | 31,800 0.0055% | $91.02 | $2.89M | -2.96% | |
| 2026-08-26 | Sale | Markowitz Wayne | CVP, JAPAC | 1,240 0.0002% | $91.47 | $113,417 | -2.96% | |
| 2026-08-11 | Sale | Lippis Daniel J. | CVP, TAVR | 619 0.0001% | $92.03 | $56,967 | -5.62% | |
| 2026-07-30 | Sale | Markowitz Wayne | CVP, JAPAC | 146.31 <0.0001% | $86.03 | $12,588 | +2.36% | |
| 2026-07-28 | Sale | Markowitz Wayne | CVP, JAPAC | 9,628 0.0017% | $85.06 | $818,958 | +6.14% | |
| 2026-07-27 | Sale | Zovighian Bernard J | CEO | 2,920.55 0.0005% | $83.93 | $245,134 | +6.94% | |
| 2026-07-10 | Sale | Lippis Daniel J. | CVP, TAVR | 619 0.0001% | $91.70 | $56,762 | -4.25% | |
| 2026-06-30 | Sale | Lippis Daniel J. | CVP, TAVR | 619 0.0001% | $91.40 | $56,577 | -1.84% | |
| 2026-06-17 | Sale | Zovighian Bernard J | CEO | 523 <0.0001% | $87.92 | $45,982 | +2.56% | |
| 2026-05-29 | Sale | Dahl Andrew M. | SVP, Corporate Controller | 567.53 <0.0001% | $86.08 | $48,853 | +2.07% | |
| 2026-05-27 | Sale | BOBO DONALD E JR | CVP,Strategy/Corp Development | 23,145 0.004% | $86.42 | $2M | +2.01% | |
| 2026-05-22 | Sale | Chopra Daveen | CVP, TMTT & Surgical | 1,500 0.0003% | $84.60 | $126,905 | +2.77% | |
| 2026-05-18 | Sale | Lippis Daniel J. | CVP, TAVR | 620 0.0001% | $81.14 | $50,307 | +6.91% | |
| 2026-05-15 | Sale | BOBO DONALD E JR | CVP,Strategy/Corp Development | 17,968 0.0031% | $81.96 | $1.47M | +8.09% | |
| 2026-05-12 | Sale | Zovighian Bernard J | CEO | 36,351 0.0062% | $77.93 | $2.83M | +9.95% | |
| 2026-05-11 | Sale | Markowitz Wayne | CVP, JAPAC | 593 0.0001% | $79.73 | $47,280 | +13.52% |
| Zovighian Bernard J | CEO | 8916 0.0015% | $848,680.71 | 1 | 16 | <0.0001% |
| GALLAHUE KIERAN | director | 67219 0.0117% | $6.4M | 2 | 2 | +27.32% |
| VALERIANI NICHOLAS J | director | 63811 0.0111% | $6.07M | 1 | 1 | <0.0001% |
| LORANGER STEVEN R | director | 60372 0.0105% | $5.75M | 1 | 1 | <0.0001% |
| PYOTT DAVID E I | director | 48429 0.0084% | $4.61M | 1 | 6 | +10.01% |
| MCNEIL BARBARA J | director | 46454 0.0081% | $4.42M | 1 | 5 | +33.89% |
| Szyman Catherine M. | CVP, Critical Care | 34814 0.006% | $3.31M | 1 | 56 | +31.99% |
| VON SCHACK WESLEY W | director | 8000 0.0014% | $761,520.00 | 3 | 6 | +20.17% |
| Increased Positions | 617 | +43.24% | 37M | +7.43% |
| Decreased Positions | 594 | -41.63% | 32M | -6.29% |
| New Positions | 179 | New | 5M | New |
| Sold Out Positions | 104 | Sold Out | 5M | Sold Out |
| Total Postitions | 1,450 | +1.61% | 507M | +1.14% |
| Vanguard Group Inc | $6M | 12.13% | 70.36M | +365,581 | +0.52% | 2025-09-30 |
| Blackrock, Inc. | $4.63M | 9.36% | 54.29M | -1M | -2.43% | 2025-09-30 |
| State Street Corp | $2.19M | 4.42% | 25.62M | -14,746 | -0.06% | 2025-09-30 |
| Jpmorgan Chase & Co | $2.14M | 4.32% | 25.06M | -2M | -6.41% | 2025-09-30 |
| Wellington Management Group Llp | $1.78M | 3.59% | 20.8M | +977,933 | +4.93% | 2025-09-30 |
| Bank Of New York Mellon Corp | $1.62M | 3.28% | 19.01M | +1M | +8.09% | 2025-09-30 |
| Fmr Llc | $1.24M | 2.51% | 14.58M | +12M | +476.71% | 2025-09-30 |
| Jennison Associates Llc | $1.19M | 2.41% | 13.96M | +2M | +19.6% | 2025-09-30 |
| Geode Capital Management, Llc | $1.1M | 2.21% | 12.84M | +114,729 | +0.9% | 2025-09-30 |
| Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt | $788,466.00 | 1.59% | 9.24M | +110,840 | +1.21% | 2025-09-30 |